These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28265509)

  • 1. New
    Kischkel FC; Eich J; Meyer CI; Weidemüller P; Krapfl J; Yassin-Kelepir R; Job L; Fraefel M; Braicu I; Kopp-Schneider A; Sehouli J; De Wilde RL
    PeerJ; 2017; 5():e3030. PubMed ID: 28265509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).
    Kischkel FC; Meyer C; Eich J; Nassir M; Mentze M; Braicu I; Kopp-Schneider A; Sehouli J
    J Ovarian Res; 2017 Oct; 10(1):72. PubMed ID: 29078793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
    Chawla D; Kar R; Gupta B; Halder S; Garg S; Mehndiratta M; Wadhwa N; Agarwal R
    Int J Gynecol Cancer; 2018 Jul; 28(6):1239-1246. PubMed ID: 29727353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of primary culture of human ovarian cancer cells to chemotherapy: In vitro individualized therapy.
    Kar R; Sharma C; Sen S; Jain SK; Gupta SD; Singh N
    J Cancer Res Ther; 2016; 12(2):1050-5. PubMed ID: 27461697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Sevin BU; Perras JP
    Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
    Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
    Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
    Qiu F; Zhao X
    J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents.
    Gravett AM; Dennis JL; Dalgleish AG; Copier J; Liu WM
    Oncol Lett; 2020 Dec; 20(6):321. PubMed ID: 33093925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
    Engblom P; Rantanen V; Kulmala J; Grènman S
    Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
    Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Kollmannsberger C; Beyer J; Jonas U; Kanz L
    World J Urol; 1998; 16(2):155-62. PubMed ID: 12073232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA).
    Larsson R; Fridborg H; Kristensen J; Sundström C; Nygren P
    Br J Cancer; 1993 May; 67(5):969-74. PubMed ID: 8494730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients.
    Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Imamura F; Minamikawa K; Takano T; Kobayashi H
    Lung Cancer; 2010 Jun; 68(3):472-7. PubMed ID: 19660825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
    Jonsson E; Fridborg H; Nygren P; Larsson R
    Eur J Clin Pharmacol; 1998 Sep; 54(7):509-14. PubMed ID: 9832291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of Docetaxel and Disulfonate Tetraphenyl Chlorin in One Nanoparticle Produces Strong Synergism between Chemo- and Photodynamic Therapy in Drug-Sensitive and -Resistant Cancer Cells.
    Gaio E; Conte C; Esposito D; Miotto G; Quaglia F; Moret F; Reddi E
    Mol Pharm; 2018 Oct; 15(10):4599-4611. PubMed ID: 30148955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific dose scheduling of bimodal radioimmunotherapy and chemotherapy.
    Blumenthal RD; Leone E; Goldenberg DM
    Anticancer Res; 2003; 23(6C):4613-9. PubMed ID: 14981904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.